Should premenopausal HR+ve breast cancer receive LHRH?
|
|
- Arabella Jennings
- 5 years ago
- Views:
Transcription
1 Should premenopausal HR+ve breast cancer receive LHRH? Hesham Elghazaly, MD Prof. Clinical Oncology, Ain Shams University President of the BGICS
2 Should premenopausal HR+ve breast cancer receive LHRH? NO? Side effects YES Efficacy Evidence
3 What is the evidence behind LHRH in HR+ve early breast cancer? OA vs No TTT OA + Tam vs Tam OA vs Chemo OA + Tam vs Chemo OA + AI vs OA +Tam vs Tam
4 Percentage OA vs No TTT Early Breast Cancer Trialists Group Overview 2005: Ovarian Ablation No Chemotherapy: Ovarian Ablation vs Not All Deaths % 62.7% 56.7% 66.6% 6.1% (SE 2.9) 54.3% 8.3% (SE 3.0) 46.3% 10.4% (SE 3.1) Reduction in the risk of Recurrence: 31% Death from BC: 31% Mortality: 28% 20 < 50 Actuarial estimate and SE - Allocated ABLATION - Allocated CONTROL Years Early Breast Cancer Trialists Collaborative Group (EBCTCG). Lancet. 2005;365:
5 OA + Tam vs Tam ZIPP: Study Design Goserelin x 2 years Premenopausal ER+ and/or PgR+ Node positive Randomize N = 2631 Tamoxifen x 2 years Goserelin x 2 years plus tamoxifen x 2 years No further treatment Goserelin and tamoxifen administered for 5 years Rutqvist LE. ASCO Abstract 251.
6 ZIPP: Results Goserelin arms had significantly better DFS and trend toward better OS compared with no goserelin, particularly for ER+ patients HR: 0.77; 95% CI: ; P <.001 Rutqvist LE. ASCO Abstract 251.
7 Ovarian Suppression vs Chemotherapy
8 OA vs Chemo DFS OS ZEBRA CMFx 6cycles Vs Goserline ND ND IBCSGVIII CMF Vs Goserline Vs CMF +Goserline ND Better in < 40 ys ND TABLE CMF x6 vs Leupron 2 years ND ND
9 Randomization ZEBRA: Study Design CMF x 6 cycles N = 1640; Premenopausal Lymph node positive ER+/ER- Goserelin 3.6 mg q 28 days x 2 yrs Median follow-up: 7.3 yrs Kaufmann M, et al. Eur J Cancer. 2003;39:
10 Proportion Alive and Disease Free ZEBRA: Disease-Free Survival (DFS) in ER+ Subgroup (a) HR: 1.05; 95% CI: Patients at risk at the start of each year Time (Years) Reprinted from Kaufmann M, et al. Eur J Cancer. 2003;39: , with permission from Elsevier Goserelin CMF
11 ZEBRA: Overall Survival in ER+ Subgroup No difference in overall survival between CMF and goserelin in ER+ subgroup HR = 0.94; 95% CI: Kaufmann M, et al. Eur J Cancer. 2003;39:
12 Patients with amenorrhoea (%) ZEBRA: Effect of Treatment on Amenorrhoea Rates ZOLADEX 3.6mg CMF Time after entry (years) Jonat W, et al. J Clin Oncol 2002; 20:
13 Percentage change from baseline Lumbar Spine Percentage change from baseline 0-2 p= p= NS ZOLADEX 3.6mg CMF Years Fogelman I, et al. Osteoporosis Int 2003; 14:
14 ZEBRA: Quality of Life (QoL) 86 centres: ZOLADEX 3.6mg, n=514; CMF, n=496 Early benefits (3 6 months) with ZOLADEX 3.6mg vs CMF treatment (p< ) overall QoL score physical symptom distress score effort to cope with illness activity level No significant difference in overall QoL between groups after 6 months de Haes H, et al. J Clin Oncol 2003; 21:
15 Randomization IBCSG VIII: Study Design CMF x 6 cycles (n = 360) N = 1063 Premenopausal Lymph node negative ER+/ER- Goserelin x 2 years (n = 346) CMF x 6 cycles followed by goserelin x 18 months (n = 367) Castiglione-Gertsch M, et al. J Natl Caner Inst. 2003;95:
16 IBCSG VIII: DFS for ER+ N0 by Age 5-year DFS similar with all therapies in ER+ patients age 39 Years CMF + goserelin, 89%; goserelin, 85%; CMF, 85% (P =.90 5-year DFS significantly improves with CMF + goserelin in ER+ women 39 Years CMF + goserelin, 88%; goserelin, 63%; CMF, 62% (P =.04 Castiglione-Gertsch M, et al. J Natl Caner Inst. 2003;95:
17 N = 600, lymph node positive, ER+ CMF x 6 cycles or leuprolide x 2 years Ovarian suppression with leuprorelin acetate was as effective as standard chemotherapy in terms of Recurrence-free Overall survival Most common adverse events Leuprolide CMF TABLE Study Low-grade hot flashes, weight gain, and increased sweating Alopecia, nausea, and vomiting Schmid P, et al. Anticancer Res. 2002;22:
18 Ovarian Suppression plus Tamoxifen Compared With Chemotherapy
19 OA + Tam vs chemo TRIAL Study Population HR+ve Protocol DFS /OS ABCSG LN -ve CMFx6 vs Goserlinex3y+Tamx5y Better DFS GROCTA LN-ve or +ve CMFx6 vs Any OS+ Tam Same DFS and OS French Adj study group 1-3 LN +ve FEC vs LHRH + Tam Same DFS and OS ECOG5188/INTERG ROUP pt LN+ve CAF vs CAF + Goserline vs CAF+ Goserline+ Tam betterdfs esp < 40y
20 ABCSG Trial 5 N = 1034, lymph node negative or positive, ER+ Regimens CMF x 6 cycles Goserelin x 3 years plus tamoxifen x 5 years Median follow-up: 60 months Results Goserelin plus tamoxifen better than CMF for DFS HR: 1.40; 95% CI: ; P =.017 Jakesz R, et al. J Clin Oncol. 2002;20:
21 Relapse-Free Survival* (%) Overall Survival (%) Austrian Breast and Colorectal Cancer Study Group: Tam x 5 Yrs and OS x 3 Yrs vs CMF 100 Tamoxifen + Goserelin 100 Tamoxifen + Goserelin CMF CMF Patients at risk Endocrine therapy Chemotherapy Months * Kaplan-Meier estimates of RFS in the group assigned to endocrine therapy (taxoxifen and goserelin) and the group assigned to chemotherapy (CMF). Differences between groups were significant (P =.017, generalized Wilcoxon test; P =.037, log-rank test). Figures of patients at risk are included 60 Patients at risk Endocrine therapy Chemotherapy Months Kaplan-Meier estimates of OS in the group assigned to endocrine therapy (tamoxifen and goserelin) and the group assigned to chemotherapy (CMF). Differences between groups were not significant (P =.093, generalized Wilcoxon test; P =.195, log-rank test). Figures of patients at risk are included. Jakesz R, et al. J Clin Oncol. 2002;20(24): Reprinted with permission from the American Society of Clinical Oncology.
22 GROCTA 02 N = 244, lymph node negative or positive, ER+ Regimens OS (surgery, radiation, or goserelin x 2 years) + tamoxifen 30 mg x 5 years (n = 124) CMF x 6 cycles (n = 120) Results Median follow-up: 76 months Goserelin + tamoxifen comparable to CMF for DFS and OS Recurrence: HR: 0.94; P =.80 Death: HR: 0.69; P =.3 Boccardo F, et al. J Clin Oncol. 2000;18:
23 Percent Surviving Overall and Disease-Free Survival Curves 1.0 Overall Survival.5 Disease Free Boccardo F, et al. J Clin Oncol. 2000;18: Reprinted with permission from the American Society of Clinical Oncology. Copyright American Society of Clinical Oncology 0 CMF TMX+OS Overall Survival CMF TMX + OS Disease-Free Survival CMF TMX + OS Patients at risk Years
24 French Adjuvant Study Group Trial 06 Premenopausal women, N = 333, 1-3 positive nodes, ER+ Regimens Tamoxifen 30 mg plus triptorelin 3.75 mg IM every month x 3 years (n = 164) FEC x 6 cycles (n = 169) Results 54 months of median follow-up Tamoxifen plus triptorelin vs chemotherapy DFS: 91.7% vs 80.9% (NS) OS: 97.0% vs 92.9% (NS) Roche HH, et al. ASCO Abstract 279.
25 ECOG 5188/Intergroup Trial 0101 CAF N = 1503 Lymph node positive Hormone receptor positive Randomize CAF + goserelin CAF + goserelin + tamoxifen Goserelin and tamoxifen administered for 5 years Davidson NE, et al. J Clin Oncol. 2005;23:
26 E5188/INT 0101: DFS for Women < 40 Years of Age Improvement in 9-year DFS with CAF plus goserelin over CAF in women < 40 years of age Tamoxifen + CAF + goserlein 9-year DFS: 64% CAF + goserelin 9-year DFS: 55% CAF 9-year DFS: 48% Suggests possible treatment benefit in younger women with addition of ovarian suppression Davidson NE, et al. J Clin Oncol. 2005;23:
27 E5188/INT 0101: Survival No difference in overall survival when tamoxifen added to CAF plus goserelin compared with CAF or CAF plus goserelin Tamoxifen + CAF + goserlein 9-year OS: 76% (P = NS) CAF + goserelin 9-year OS: 73% (P = NS) CAF 9-year OS: 70% Significance not achieved after 9 years Davidson NE, et al. J Clin Oncol. 2005;23:
28 Chemotherapy regimen Reported Amenorrhoea Rates for Chemotherapy Regimens % of women becoming amenorrhoeic Women aged years Women aged 40 years CMF (6 months) 1 CAF or FEC (3 6 months) 1 AC (3 months) 1 CEF (6 months) Burstein HJ, Winer EP. N Engl J Med 2000; 343: ; 2. Parulekar W, et al. Proc Am Soc Clin Oncol 2001; 20: 25a, Abstr 97
29 OA + AI vs OA +Tam vs Tam
30 Adjuvant Ovarian Suppression in Premenopausal Breast Cancer ( SOFT trial) N Engl J Med 2015;372: DOI: /NEJMoa Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer (TEXT trial) N Engl J Med 2014;371: DOI: /NEJMoa
31 TEXT SOFT Designs TEXT (N=2672) Enrolled: Nov 03-Apr11 Premenopausal > 12 weeks after surgery planned OFS NO planned Chemo OR planned Chemo. SOFT (N=3066) Premenopausal > 12 weeks after surgery planned OFS NO planned Chemo OR remain premenopausal > 8 months after chemo. R A N D O M I Z A T I O N R A N D O M I Z A T I O N Tamoxifen + OFS 5Y Exemestane + OFS 5Y Tamoxifen 5Y Tamoxifen + OFS 5Y Exemestane + OFS 5Y Joint Analysis (N=4690) Tamoxifen + OFS 5Y Exemestane + OFS 5Y Median follow up 5.7 Y Adapted from Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
32 Eligibility Premenopausal women with HR+ (ER and/or PgR <10%) Proper Local-regional treatment with no residual disease. Randomized within 12 weeks of surgery for all women in TEXT & SOFT who didn t receive Chemotherapy. Women in SOFT who received prior (neo)adjuvant chemotherapy randomized >8 months of chemotherapy completion when premenopausal status demonstrated. These patients were permitted to receive oral endocrine therapy prior to rendomization. Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
33 Treatment Protocol treatment was for 5 Years from randomization. Ovarian Function Suppression TEXT SOFT All women started with GnRH agonist triptorelin (IM q28d). Triptorelin initiated concurrently with chemotherapy, if it was given. Bilateral oophorectomy or irradiation as alternative to triptorelin(decapeptyl, Diphereline and Gonapeptyl ) after 6 months. Choice of OFS Method. Oral Endocrine therapy Exemestan 25mg daily, or Tamoxifen 20 mg daily. In TEXT Started 6 to 8 weeks after initiation of OFS, or After Chemotherapy if given. Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
34 Study Procedures Adjuvant Trastuzumab allowed, if indicated. Annual mammography and bone densitometry recommended. Targeted A.Es and other grade 3-5 A.Es (CTCAE v3.0) QOL Self assessment of Global & Sympto-Specific Indicators. Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
35 Primary: Disease Free Survival (DFS) Endpoints o Invasive recurrence (Local, Regional, Distant) o Invasive Contralateral Breast Cancer. o Second (non-breast) invasive malignancy. o Death without prior cancer event. Secondary Breast Cancer Free interval (BCFI) o Invasive recurrence or contralateral Breast Cancer. Distant recurrence free interval (DRFI) o Distant Recurrence. Overall Survival (OS) o Death from any cause. Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
36 Characteristics No Chemo TEXT (N=1053) No Chemo SOFT (N=943) Chemo TEXT (N=1607) Prior Chemo SOFT (N=1087) Overall (N=4690) Age < 40 Y 16% 9% 30% 49% 27% LN + 21% 8% 66% 57% 42% T-Size > 2 cm 19% 15% 53% 47% 36% Surgery to Random (median) HER2 + 5% 3% 17% 19% 12% 1.5 mo 1.8 mo 1.2mo mo Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
37 Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
38 4% absolute improvement in 5-Y freedom from breast cancer for exemestane + OFS No Significant difference in Overall survival Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
39 Some Women have excellent prognosis with highly effective endocrine therapy alone >97% breast cancer-free at 5 years when treated with exemestane + OFS Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
40 Absolute improvement with exemestan + OFS 5 Y freedom from breast cancer: 5.5% in TEXT and 3.9% in SOFT 5 Y freedom from distant recurrence: 2.6% in TEXT and 3.4% in SOFT Supplementary appendix of, Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
41 Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. This article was published on June 1, 2014, at NEJM.org.
42 The DFS was RESULTS 92.8% in the exemestane plus ovarian S group, 88.8%in the tamoxifen + ovarian suppression (HR for recurrence, 0.66;95% CI, ;P<.001) The OS did not differ significantly between groups. Women at high risk of recurrence who received prior chemotherapy had improved outcome with ovarian suppression their chance to be disease free at 5 years 78% with Tamoxifen alone, 82% with tamoxifen and ovarian suppression, 85.7% with exemestane and ovarian susupression. In the cohort of women with no prior chemotherapy, no meaningful benefit was seen from ovarian suppression as women who received tamoxifen alone has 95% chance of remaining disease free for 5 years
43 GUIDELINES
44 Ovarian Ablation in Early Breast Cancer: an overview of the randomized trials ( I ) TABLE 6. Meta-analysis of the Effect of Ovarian Ablation Reduction in Reduction Annual Odds Annual Odds Group of Recurrence (%) of Death (%) Ovarian ablation vs. no adju vant therapy (age < 50) Ovarian ablation + chemo therapy vs chemotherapy Adapted from EBCTCG Lancet 1996;348:
45
46 Dr. Heba plz save my life.. Don t say NO Reversible side effect Efficacy DFS
38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationA review of adjuvant hormonal therapy in
REVIEW Endocrine-Related Cancer (2004) 11 391 406 A review of adjuvant hormonal therapy in breast cancer Kellie L Jones and Aman U Buzdar 1 Department of Pharmacy, University of Texas M.D. Anderson Cancer
More informationJOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E
NUMBER MARCH VOLUME 23 d 8 d 10 2005 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer Silvia Dellapasqua, Marco Colleoni,
More informationКой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго?
Кой има полза от адювантна ендокринна терапия при карцином на гърда с какво и колко дълго? д-р Красимир Койнов МБАЛ Сердика, София Декларация Консултации и хонорари: Roche, Boerhinger Ingelheim, Astra
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
he new england journal of medicine Original Article he authors full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Francis at the Peter MacCallum
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients
More informationOvarian Ablation as Adjuvant Therapy for Breast Cancer
Ovarian Ablation as Adjuvant Therapy for Breast Cancer Nancy E. Davidson Ovarian ablation was the first form of systemic treatment for breast cancer. Its efficacy as a palliative treatment for young women
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationIntroduction. pissn , eissn Open Access. Original Article
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(1):55-63 Original Article http://dx.doi.org/10.4143/crt.2013.165 Open Access Ovarian Ablation Using Goserelin Improves Survival of Premenopausal
More informationATAC Trial. 10 year median follow-up data. Approval Code: AZT-ARIM-10005
ATAC Trial 10 year median follow-up data Approval Code: AZT-ARIM-10005 Background FDA post-approval commitment analysis to update DFS, TTR, OS and Safety Prof. Jack Cuzick on behalf of ATAC/LATTE Trialists
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationDisclosures. ASCO Highlights Breast Cancer. Associa4on of Northern California Oncologists 8/25/14
ASCO Highlights 2014 Associa4on of Northern California Oncologists Breast Cancer Sco+ Christensen, MD Professor, Hematology/Oncology UC Davis Comprehensive Cancer Center Disclosures 1 Outline Novel TherapeuFcs/Early
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationHORMONAL THERAPY IN ADJUVANT CARE
ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER* Matthew J. Ellis, MD, PhD ABSTRACT Endocrine therapy is used frequently in breast cancer management, particularly in the setting of adjuvant care, but outstanding
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationYukinori Ozaki 1 Yuko Tanabe 1 Nobuko Tamura 2 Takuya Ogura 2 Chihiro Kondoh 1 Yuji Miura 1 Kenichi Yoshimura 3 Hidetaka Kawabata 2 Toshimi Takano 1
https://doi.org/10.1007/s12282-018-0836-x ORIGINAL ARTICLE Impact on disease free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with
More informationThe Three Ages of Systemic Adjuvant Therapy for EBC
The Three Ages of Systemic Adjuvant Therapy for EBC 1896-2018 Nicholas Wilcken Westmead Hospital Petersham Institute University of Sydney Questions to be answered (concentrating on chemotherapy) Why should
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationResearch Article Biological Characteristics and Medical Treatment of Breast Cancer in Young Women A Featured Population: Results from the NORA Study
SAGE-Hindawi Access to Research International Breast Cancer Volume 2, Article ID 534256, 6 pages doi:.46/2/534256 Research Article Biological Characteristics and Medical Treatment of Breast Cancer in Young
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationTHE ADJUVANT treatment of premenopausal patients with
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationAdjuvant Ovarian Suppression in Premenopausal Breast Cancer
The new england journal of medicine original article Adjuvant Ovarian Suppression in Premenopausal Breast Cancer Prudence A. Francis, M.D., Meredith M. Regan, Sc.D., Gini F. Fleming, M.D., István Láng,
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2011 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationINTERGROUP EXEMESTANE STUDY Updated survival analysis
INTERGROUP EXEMESTANE STUDY Updated survival analysis R Charles Coombes, Emma Hall, Claire F Snowdon, Lesley Fallowfield, Rob Coleman, Gianfillipo Bertelli and Judith M Bliss, on behalf of the Intergroup
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationAdvances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD
Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:
More informationTAILORx: Established and Potential Implications for Clinical Practice
TAILORx: Established and Potential Implications for Clinical Practice Joseph A. Sparano, MD Study Chair, TAILORx Vice-Chair, ECOG-ACRIN Cancer Research Group Hello Healthcare Summit Berlin, Germany March
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationShe counts on your breast cancer expertise at the most vulnerable time of her life.
HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 3 JANUARY 2 2 JOURNAL OF CLINICAL ONCOLOGY S P E C I A L A R T I C L E From the Academic Department of Biochemistry, Royal Marsden Hospital; Cancer Research UK Centre for Epidemiology,
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More information1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical
1 2 1. Hammond ME et al.. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast
More informationSan Antonio Breast Cancer Symposium 2013
15 th Annual Advances in Oncology Navigating Breast Cancer Therapeutics: Early and Late Stage Disease Scott Christensen, MD Professor, Hematology/Oncology UC Davis Comprehensive Cancer Center 15th Annual
More informationJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
The Oncologist Breast Cancer What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today? TATIANA M. PROWELL, NANCY E. DAVIDSON Johns Hopkins Sidney Kimmel Comprehensive
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationEndocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment
Review Article Page 1 of 12 Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment Jun-Jie Li, Zhi-Min Shao Department of
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationAdvances in Breast Cancer ASCO 2018
Advances in Breast Cancer ASCO 2018 Wylie Hosmer, MD Hartford Healthcare Cancer Institute Special Thanks to Dawn Holcombe for help with slide preparation TAILORx ASCO Highlights HER2 6 vs 12 Long Term
More informationIntroduction. pissn , eissn Open Access. Original Article
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 216;48(4):1351-1362 Original Article http://dx.doi.org/1.4143/crt.215.444 Open Access Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair
More informationThe first randomized clinical trial of adjuvant
ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER Aman U. Buzdar, MD* ABSTRACT The safety and efficacy of tamoxifen as adjuvant endocrine therapy for postmenopausal patients
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationJournal of Breast Cancer
REVIEW ARTICLE Journal of Breast Cancer J Breast Cancer 2016 December; 19(4): 341-348 Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer Woo-Chan Park Department of Surgery,
More information